1. Murata F, Maeda M, Murayama K, Nakao T, Fukuda H. Incidence of post-COVID psychiatric disorders according to the periods of SARS-CoV-2 variant dominance: The LIFE study. Journal of Psychiatric Research 2024; 174: 12-18.
2. Murata F, Maeda M, Murayama K, Nakao T, Fukuda H. Associations between COVID-19 vaccination and incident psychiatric disorders after breakthrough SARS-CoV-2 infection: The VENUS Study. Brain Behavior and Immunity 2024; 117: 521-528.
3. Maeda M, Murata F, Fukuda H. The Age-Specific Impact of COVID-19 Vaccination on Medical Expenditures and Hospitalization Duration After Breakthrough Infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. Vaccine 2024; 42(7): 1542-1548.
4. Murata F, Maeda M, Ono R, Fukuda H. Association Between Regular Physical Activity and Pneumonia-Related Hospitalization According to Pneumococcal Vaccination Status: The VENUS Study. Vaccine 2024; 42(6): 1268-1274.
5. Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H. Bivalent mRNA Vaccine Effectiveness and Hybrid Immunity against COVID-19 among Older Adults in Japan: A Test-negative Study from the VENUS Study. BMC Infectious Diseases 2024; 24(1): 135.
6. Sato S, Kawazoe Y, Katsuta T, Fukuda H. Comparison design and evaluation power in cohort and self- controlled case series designs for post-authorization vaccine safety studies. PeerJ 2024; 12: e16780.
7. Yamada N, Nakatsuka K, Tezuka M, Murata F, Maeda M, Akisue T, Fukuda H, Ono R. Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study. Vaccine 2024; 42(2): 239-245.
8. Sato S, Katsuta T, Kawazoe Y, Takahashi M, Murata F, Maeda M, Fukuda H, Kamidani S. Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Vaccine 2024; 42(1): 4-7.
9. Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Maeda M, Murata F, Fukuda H. Bivalent vaccine effectiveness among older adults aged >=65 years during the BA.5 predominant period in Japan: the VENUS Study. Open Forum Infectious Diseases 2023; 10(10): ofad475.
10. Tsuzuki S, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H. The association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-2016 to 2020-2021 seasons: from the VENUS study. Journal of Antimicrobial Chemotherapy 2023; 78(12): 2976-2982.